MedTrace Logo

Real Life Safety and Efficacy of Vardenafil

NCT01215409 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 372

Last updated 2014-05-19

No results posted yet for this study

Summary

In this uncontrolled, non-randomized, prospective, local post-marketed surveillance study, data are obtained on safety and efficacy of LEVITRA® in routine treatment of erectile dysfunction. The general objectives are to evaluate the product safety (primarily by recording adverse events), efficacy and patient acceptance.

Conditions

Interventions

DRUG

Vardenafil (Levitra, BAY38-9456)

5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Taiwan

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215409 on ClinicalTrials.gov